Skip to main content
رجوع
SNDX logo

Syndax Pharmaceuticals, Inc.

جودة البيانات: 100%
SNDX
NASDAQ Healthcare Biotechnology
KWD 24.02
▼ KWD 0.07 (-0.29%)
القيمة السوقية: 2.12B
نطاق اليوم
KWD 23.60 KWD 24.41
نطاق 52 أسبوعًا
KWD 8.58 KWD 25.44
حجم التداول
1,100,986
متوسط 50 يوم / 200 يوم
KWD 21.50 / KWD 16.47
الإغلاق السابق
KWD 24.09

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (627 نظير)

المقياس السهم وسيط القطاع
P/E -7.4 0.3
P/B 32.8 2.9
ROE % -161.8 3.7
Net Margin % -165.6 3.8
Rev Growth 5Y % 5.4 10.0
D/E 5.4 0.2

السعر المستهدف للمحللين

Hold
KWD 39.330 +63.7%
Low: KWD 35.000 High: KWD 45.000
ربحية السهم المستقبلية
-KWD 1.588
الإيرادات المقدّرة
370 M

تقديرات الأرباح

الفترة تقدير ربحية السهم تقدير الإيرادات المحللون
FY2030 KWD 3.408
KWD 2.440 – KWD 4.615
1.1 B 5
FY2029 KWD 2.418
KWD 1.731 – KWD 3.274
910 M 2
FY2028 KWD 1.025
-KWD 0.009 – KWD 2.326
760 M 7

النقاط الرئيسية

Revenue grew 5.39% annually over 5 years — modest growth
Debt/Equity of 5.36 — high leverage
Negative free cash flow of -323.17M
PEG of 0.55 suggests growth is underpriced
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 622.45%
Capital efficient — spends only 0.11% of revenue on capex

النمو

Revenue Growth (5Y)
5.39%
Revenue (1Y)627.84%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

الجودة

Return on Equity
-161.82%
ROIC-49.82%
Net Margin-165.60%
Op. Margin-158.45%

الأمان

Debt / Equity
5.36
Current Ratio4.40
Interest Coverage-8.08

التقييم

P/E Ratio
-7.42
P/B Ratio32.78
EV/EBITDAN/A
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 627.84% Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 5.39% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 172.35M Net Income (TTM) -285.42M
ROE -161.82% ROA -53.88%
Gross Margin 95.96% Operating Margin -158.45%
Net Margin -165.60% Free Cash Flow (TTM) -323.17M
ROIC -49.82% FCF Growth (3Y) N/A
Safety
Debt / Equity 5.36 Current Ratio 4.40
Interest Coverage -8.08 Dividend Yield 0.00%
Valuation
P/E Ratio -7.42 P/B Ratio 32.78
P/S Ratio 12.29 PEG Ratio 0.55
EV/EBITDA N/A Dividend Yield 0.00%
Market Cap 2.12B Enterprise Value 2.33B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 172.35M 23.68M 0.0 0.0 139.71M
Net Income -285.42M -318.76M -209.36M -149.34M 24.93M
EPS (Diluted) -3.30 -3.73 -2.98 -2.46 0.48
Gross Profit 165.38M 22.85M 0.0 0.0 139.71M
Operating Income -273.08M -339.67M -229.95M -151.76M 26.22M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 529.71M 724.82M 612.88M 497.24M 449.66M
Total Liabilities 465.08M 436.69M 58.68M 29.79M 41.29M
Shareholders' Equity 64.63M 288.12M 554.20M 467.45M 408.37M
Total Debt 346.48M 345.74M 1.64M 1.16M 20.97M
Cash & Equivalents 134.93M 154.08M 295.39M 74.36M 221.97M
Current Assets 528.08M 603.06M 580.88M 489.79M 448.40M
Current Liabilities 120.12M 103.55M 58.10M 29.07M 20.68M